Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research report report published on Friday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 1.5 %

Shares of LPCN stock opened at $3.35 on Friday. Lipocine has a 1 year low of $2.91 and a 1 year high of $11.79. The firm’s 50 day moving average is $3.95 and its 200-day moving average is $4.52. The firm has a market capitalization of $17.92 million, a price-to-earnings ratio of -4.41 and a beta of 1.42.

Hedge Funds Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC increased its holdings in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the period. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 at the end of the most recent quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.